Background {#Sec1}
==========

Mutations in receptor tyrosine kinases (RTKs) genes have been identified as the main cause of many carcinomas development, since they can lead to proliferation and transformation of cancer cells \[[@CR1]\]. In recent years, ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), a gene located on 6q22, which transcripts the protein that belongs to the subfamily of tyrosine kinase insulin receptor, has been recognized as a driver of non-small cell lung cancer (NSCLC) \[[@CR2]\] since it can fuse with other genes (e.g. CD74, SLC34A2, FIG, TPM3, SDC4, EZR, LRIG3, CCDC6, and KDELR2 \[[@CR3], [@CR4]\]) and consequently activate the downstream growth and survival signaling pathways \[[@CR3]--[@CR7]\]. In most cases, ROS1 fusion rearrangement is exclusive to other RTK aberrance, such as the anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement, epidermal growth factor receptor (EGFR) mutations and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations \[[@CR4]\]. Moreover, because of the homology between the ROS1 and ALK proteins \[[@CR8], [@CR9]\], patients with ROS1 rearrangement are sensitive to ALK tyrosine kinase inhibitors (TKIs). Therefore, despite the incidence of ROS1 rearrangements in NSCLC is low (1--2 %) \[[@CR4], [@CR10]\], screening ROS1 rearrangement could be potentially beneficial for NSCLC patients.

In the present work, fluorescent *in situ* hybridization (FISH), quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) have been used for ROS1 arrangement detection. All of these methods have advantages and limitations. FISH analysis can reveal the genes rearrangement status, but the procedure is inconvenient \[[@CR11], [@CR12]\], and it is not suitable for biopsies with insufficient numbers of tumor cells. qRT-PCR analysis can reveal fusion rearrangements by using specific primers and it has a high sensitivity. However, qRT-PCR cannot detect specimens with unknown fusion types \[[@CR11], [@CR12]\]. IHC is feasible in large scale screening, and the D4D6 rabbit monoclonal antibody (mAb) has been identified as effective and specific mAb for ROS1 rearrangement protein detection by several studies \[[@CR3], [@CR8], [@CR11]\]. In addition, the costs to perform IHC are less compared with qRT-PCR or FISH. However, there is not an accurate cutoff value to define positive ROS1 protein expression using IHC, thus representing a limitation on using this method \[[@CR11]--[@CR14]\]. Therefore, the aim of this study was to compare these three analytical methods in their ability to detect ROS1 rearrangement in NSCLC, trying to set up a cutoff value for ROS1 IHC analysis. In addition, we investigated the efficacy of TKI therapy in treating advanced NSCLC patients with ROS1 rearrangement. The characteristics of NSCLC patients harboring ROS1 rearrangement were also discussed.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Patients admitted to the First Affiliated Hospital of Guangzhou Medical University were screened and recruited for this study from November 2013 to October 2015. Patients were selected upon (1) a previous identification of NSCLC with (2) a confirmed diagnosis by IHC of p63, CK5/6, NapsinA and TTF-1 protein expression \[[@CR15]\]. A cohort of 238 NSCLC patients was included. Afterwards, all slides from the chosen cases were independently analyzed by two pathologists (X Gu & JY Wu) blinded to history and prior diagnoses. The histopathological classification was performed according to the 2015 WHO classification of lung tumors \[[@CR15]\] and the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) multidisciplinary classification \[[@CR16]\]. Appropriate specimens with sufficient tissue (\>100 tumor cells) were included.

After recruitment, the clinical information, including age, gender, smoking history, and tumor node metastasis (TNM 7th) staging were collected. In adenocarcinoma cases, the histological grading was performed by analyzing the single most predominant pattern in a case \[[@CR15]\]. According to 2015 WHO histological grading of adenocarcinoma, the grading was divided into low, intermediate and high. Another grading score system that combined the most two predominant pattern in a case was also been used, which was worked out by Sica et al. \[[@CR17]\]. The results of other genetic markers testing were also collected, such as ALK, EGFR and KRAS. Ventana IHC with D5F3 mAb and FISH with break-apart probe were used in ALK rearrangement detection. Amplification refractory mutation system polymerase chain reaction (ARMS-PCR) was used to detect EGFR and KRAS gene mutation. This study was approved by the Ethic Review Committee of the First Affiliated Hospital of Guangzhou Medical University.

Immunohistochemistry (IHC) {#Sec4}
--------------------------

All the specimens were formalin-fixed and paraffin embedded (FFPE). ROS1 IHC was performed on 4 μm slides and completed on a fully automated IHC instrument (BenchMark XT, Roche, Switzerland). D4D6 rabbit mAb (Cell Signaling Technology, Danvers, MA) diluted in 1:200 was used as primary antibody. Detection was using UltraView Universal DAB detection Kit (Roche, Switzerland). IHC was scored using the following score scheme: 0, no staining of tumor cells; 1+, tumor cells with faint cytoplasmic reactivity without any background staining; 2+, tumor cells with moderate cytoplasmic reactivity; and 3+, tumor cells with strong granular cytoplasmic reactivity \[[@CR11]\]. When several intensity levels present in a case, it was scored according to the intensity of major tumor cells. The extent of IHC staining was also analyzed by estimating the staining percentage of tumor cells \[[@CR8]\]. Moreover, H-score method was used and calculated using the following equation: H-score = ∑\[intensity (0, 1, 2, 3) × extent of each staining intensity(%)\], with a scoring range from 0 to 300 \[[@CR14]\]. Previous lung specimens with ROS1 rearrangements confirmed by FISH and a 3+ staining score, have been used as positive control. IHC was analyzed independently by two pathologists (X Gu & JY Wu), and disagreements were discussed after the analysis. A third pathologist (XG Fu) was invited as the reviewer when an agreement could not be reached. The above results were blinded for the qRT-PCR results.

Quantitative real-time polymerase chain reaction (qRT-PCR) {#Sec5}
----------------------------------------------------------

Total RNA was isolated from FFPE tissue sections (6 μm slides) using the FFPE RNA Kit (Amoy Diagnostics Co., Ltd, Xiamen, China). RNA concentration was measured using a spectrophotometer (Nanodrop 2000c, Thermo-Scientific, Wilmington, US) and reverse transcription was performed to generate complementary DNA (cDNA). The cDNA was used for multiple RT-PCRs that were carried out in an Mx3000p real-time PCR system (Agilent Technologies, California, US) using the ROS1 Gene Fusion Detection Kit (Amoy Diagnostics Co., Ltd, Xiamen, China). The positive and negative reference samples were also used. The PCR procedure was the following: One cycle at 95 °C for 5 min; 15 denaturation cycles at 95 °C for 25 s, annealing at 64 °C for 20 s and elongation at 72 °C for 20 s; 31 cycles at 93 °C for 25 s, 60 °C for 35 s (data collection) and 72 °C for 20 s. The quantification is determined by the fusion fluorescence signals and the assay with a Ct value \< 30 cycles was considered as positive. These results were blinded for the IHC and FISH results.

Tissue microarray (TMA) and fluorescent *in situ* hybridization (FISH) {#Sec6}
----------------------------------------------------------------------

IHC positive staining areas were evaluated and selected from the slides by a pathologist (JY Wu) to avoid tumor heterogeneity and the tissue microarray (TMA) was performed from the FFPE samples. Two areas of 2 mm diameter were removed from each sample block using a stainless steel stylet (Xinsen, Jieli Biomedicine Co., Ltd, Guangzhou, China). Serial 4 μm TMAs sections were used for FISH detection using 6q22 ROS1 Break Apart FISH Probe RUO Kit (Abbott Molecular Inc, IL, USA). The protocol and interpretation of FISH were the following: TMA slides were submerged in xylene and decreasing gradient of ethanol for deparaffinization and hydration, respectively. Next, they were subjected to a heat-treatment in boiled water (100 °C, 30 min) and digestion using proteinase K (37 °C, 5 min). They were washed in 2 × SSC solution and dehydrated by increasing gradient of ethanol (70 %, 85 % and 100 %) for 3--5 min. After air drying, the probe was added to the target specimens, and coverslips were placed. The slides were placed in the hybridization machine (ThermoBrite, Abbott Molecular Inc, IL, US) and hybridization was performed as follows: denaturation at 75 °C for 8 min and hybridization at 42 °C for 16 h. Next, the slides were washed in 2 × SSC and NP40 solution at 42 °C for 5 min and immersed in 70 % ethanol for 5 min. DAPI 15 μl was applied to counterstain. Analysis was performed in the dark using the fluorescence microscopy (Nikon 80i, Japan). The data analysis was the following: \>15 % tumor cells showing split signals ("red" and "green" split signals) or isolated 3′ signals (single "green" signals) belonged to the ROS1 fusion rearrangement. These results were blinded for the qRT-PCR results.

Direct sequencing {#Sec7}
-----------------

The cDNA of FISH and qRT-PCR positive cases were sent to Amoy Diagnostics Co., Ltd for direct sequencing. The results of the sequencing were compared using the Basic Local Alignment Search Tool (BLAST).

Follow-up visits {#Sec8}
----------------

After ROS1 rearrangement detection using IHC, FISH and qRT-PCR, the patients harboring ROS1 rearrangement in advanced stages (III b--IV) of disease were selected for TKI therapy. In order to track the efficacy of the therapy, information such as patient's syndromes, vital signs and CT images were collected every two months. The efficacy was evaluated using RECIST guideline 1.1 \[[@CR18]\]. The materials of patients were authorized by the recruited patients and (or) their family members.

Statistical analysis {#Sec9}
--------------------

Pearson's *χ*^2^ and Fisher's exact test were used to assess the relationship between ROS1 rearrangement, clinical characteristics and clinicopathological patterns. The Kappa value was calculated to assess the concordant rate of FISH and IHC in detecting ROS1 rearrangement. The analyses were carried out using the Statistical Package for the Social Sciences (SPSS) version 13.0 (SPSS, Inc., Chicago, IL, US), and *P* values less than 0.05 were considered statistically significant.

Result {#Sec10}
======

Characteristics of the recruited cases {#Sec11}
--------------------------------------

Two hundred and thirty-eight cases were recruited, of which 215 were surgical resection cases and 23 were needle biopsy cases. The clinical characteristics and histopathology of the patients are shown in Table [1](#Tab1){ref-type="table"}. The median age was 61 years old (range from 27 to 85 years old), and 107 were females and 131 were males. Most of the included cases were in the early stages (114/238, 47.9 %) of the disease, while 48 (48/238, 20.2 %) cases were in the advanced stages (III b--IV). Total 181 resected adenocarcinoma cases were performed histological grading, they mostly obtained score 5 in Sica staging (69/181, 38.1 %) and classified as intermediate grade in the WHO grading (126/181, 69.6 %). Details of the grading were showed in a supplementary table \[see Additional file [1](#MOESM1){ref-type="media"}: Table S1\]. However, there was no statistical difference between ROS1 rearrangement and non-rearrangement cases in clinical characteristics. Two hundred and twenty-eight patients underwent ALK rearrangement detection, 163 and 153 patients underwent EGFR and KRAS mutation detection, respectively. Among these cases, 12 cases (12/228, 5.3 %) were harboring ALK rearrangement, 87 cases (87/163, 53.4 %) and 13 cases (13/153, 8.50 %) were harboring EGFR and KRAS mutation, respectively.Table 1Characteristic of included casesCharacteristicTotalSurgery resectionBiopsyROS1 rearrangementROS1 non--rearrangement*P.*No.2382152310228Age0.114^a^\>6110910182107≤61129114158121Gender0.118^a^Male131118133128Female10797107100Smoking history0.792^a^Smoker51483348Non--smoker158140186152Previous smoker29272128Histopathology1.000^a^ADC216 (8)^b^195 (6)^b^21 (2)^b^10206 (8)^b^SCC1192011ASC22--02LCLC9 (1) ^b^9 (1) ^b^--09 (1) ^b^Adenocarcinoma subtypes (predominant pattern)^c^0.207^a^Lepidic1717--215Acinar105105--4101Papillary3333--330Micropapillary1616--214Solid2020--020Invasive mucinous adenocarcinoma88--17Fetal1101TMN stage^d^0.175^a^I11411406108II30291129III55(IIIb:10)532055IV381820335Sica grading^e^0.871^a^Score 266-06Score 34848-345Score 44848-147Score 56969-465Score 61010-010WHO grading^e^0.597^a^Low grade1717-116Intermediate grade126126-5121High grade3838-236Another gene status--ALK228 (12)^f^206 (11)^f^22 (1)^f^0228EGFR163 (87)^f^141 (78)^f^22 (9)^f^0163exon 19 deletion37334037L858R48^g^44^g^4048L861Q11001exon 20 S768I2^g^1^g^102KRAS153 (13)^f^136 (11)^f^17 (2)^f^0153Gly12Asp33003Gly12Cys44004Gly12Val44004Gly12Ala10101Gly12Ser10101Abbreviations: *ADC* Adenocarcinoma, *SCC* Squamous cell carcinoma, *ASC* Adenosquamous carcinoma, *LCLC* Large--cell lung carcinoma, *ALK* anaplastic lymphoma receptor tyrosine kinase, *EGFR* epidermal growth factor receptor, *KRAS* Kirsten rat sarcoma viral oncogene homolog^a^Fisher exact test^b^Metastasis cases^c^Total 190 resected adenocarcinoma with 200 predominant patterns were discussed. Some cases were including more than one predominant patterns^d^A case was diagnosed as stage 0^e^Total 181 resected adenocarcinoma have been analyzed, excluding variant subtypes^f^The cases with ALK rearrangement, EGFR mutation or KRAS mutation^g^There was a case harboring both exon 21 L858R and exon 20 S768I mutation

Comparison of IHC, FISH and qRT-PCR in ROS1 rearrangement detection {#Sec12}
-------------------------------------------------------------------

All the recruited patients underwent FISH and IHC detection of ROS1 rearrangement, and qRT-PCR analysis was applied in 159 cases. A total of 10 cases were confirmed as ROS1 rearrangement positive by FISH (10/238, 4.2 %; Table [2](#Tab2){ref-type="table"}). Six of them underwent qRT-PCR detection, which confirmed the presence of ROS1 rearrangement. All qRT-PCR negative cases were also confirmed as ROS1 rearrangement negative by FISH.Table 2The characteristics of patients with ROS1 rearrangementCases No.Smoking^a^Staging/Grading^b^IHC result^c^H-scoreFISH resultDirect sequencingHistopathology predominant patternStaining PatternAnother gene aberrance^d^1NII B/\
Score 5/Grade 23+/90 %260Fusion positiveSLC34A2-E4; ROS1-E32/SLC34A2-E4; ROS1-E34AcinarCytoplasmic; membraneALK\\EGFR\\KRAS(−)2NI A/Score 3/Grade 2/2+/65 %150Fusion positiveCD74-E6; ROS1-E34AcinarCytoplasmic; focal granularALK\\EGFR\\KRAS(−)3PIV/−/−2+/70 %160Fusion positiveCD74-E6; ROS1-E34Invasive mucinous adenocarcinomaMucinous stainingALK\\EGFR\\KRAS(−)4NI A/Score 5/Grade 22+/90 %200Fusion positiveTPM3-E8; ROS1-E35Papillary and acinarCytoplasmic; focal granularALK\\EGFR\\KRAS(−)5NI A/Socre 5/Grade 32+/90 %200Fusion positiveSLC34A2-E14del; ROS1-E32/SLC34A2-E14del; ROS1-E34Papillary and micropapillaryCytoplasmic; focal granularALK\\EGFR\\KRAS(−)6NIV/ Socre4/Grade 23+/85 %250Fusion positiveCD74-E6; ROS-E34AcinarCytoplasmic; granularALK\\EGFR\\KRAS(−)7^e^NIV/−/−2+/70 %160Fusion positive--Invasive adenocarcinoma with acinar patternCytoplasmic; focal granularALK\\EGFR\\KRAS(−)8SI A/Score 5/Grade 33+/90 %250Fusion positive--Papillary and micropapillaryCytoplasmic; focal granularALK\\EGFR\\KRAS(−)9SI B/Socre 3/Grade 22+/80 %180Fusion positive--Acinar and lepidicCytoplasmic; focal granularALK\\EGFR\\KRAS(−)10NI B/Score 3/Grade 12+/80 %180Fusion positive--LepidicCytoplasmic; focal granularALK\\EGFR\\KRAS(−)^a^ *N*, non-smoker; *S*, smoker; *P*, previous smoker^b^TNM staging, SICA grading and WHO grading^c^IHC results were containing intensity and extent scores^d^ALK rearrangement, EGFR and KRAS mutation have been also investigated at the sme time. The cases harboring ROS1 rearrangement were exclusive to ALK rearrangement, EGFR and KRAS mutation^e^cases 7 was biopsy sample

Forty-two cases showed cytoplasmic reactivity by IHC. Nevertheless, only ten cases with diffuse 2--3+ tumor cytoplasmic reactivity were confirmed as ROS1 rearrangement when FISH was set as the standard method. The staining was distributed in more than 60 % tumor cells (Table [2](#Tab2){ref-type="table"}; Fig. [1j](#Fig1){ref-type="fig"} & n). A setting of 2+ in intensity, 60 % in extent, and an H-score of 150 as the cutoff value represented the optimal IHC settings to reach the highest sensitivity and specificity on ROS1 rearrangement detection (Table [3](#Tab3){ref-type="table"}) \[[@CR19]\]. A concordance between FISH and IHC was found when IHC showed moderate to strong cytoplasmic reactivity (2--3+) with diffuse (≥60 %) distribution or H-score≥ 150. (*P* \< 0.01, Kappa value \> 0.6; Table [4](#Tab4){ref-type="table"}).Fig. 1Comparison of IHC, FISH and qRT-PCR in ROS1 rearrangement and non-rearrangement cases (**a**--**d**). The H&E staining, IHC, FISH and qRT-PCR results of a non-rearrangement case. **a** The case presented acinar and papillary patterns in H&E staining (200×); **b** IHC showed no staining in tumor cells (200×); **c**, **d** it was confirmed by FISH and qRT-PCR as non-rearrangement, respectively; **e**--**h** A case with weak and focal ROS1 IHC staining. **e** The case presented acinar pattern in H&E staining (200×); **f** IHC showed weak to moderate focally staining in about 40 % tumor cells (200×); **g**, **h** it was also confirmed as non-rearrangement by FISH and qRT-PCR, respectively; **i**--**l** A case with diffusely moderate IHC staining. **i** The case presented papillary and micropapillary patterns in H&E staining (200×); **j** IHC showed moderate staining with cytoplasmic and focal granular patterns in about 80 % tumor cells (200×); **k** and **l** it was proved as ROS1-rearrangement by FISH and qRT-PCR, respectively; **m-p** A case with diffusely strong IHC staining. **m** The case presented papillary and micropapillary pattern in H&E staining (200×); **n** IHC showed diffusely strong staining with cytoplasmic, membrane and granular patterns in about 90 % tumor cells (200×); **o**, **p** it was also proved as ROS1 rearrangement by FISH and qRT-PCRTable 3H-score, intensity and extent of IHCIHCFISH+FISH-SensitivitySpecificityH-score ≥501018100 %92.1 % ≥100105100 %97.8 % ≥150100100 %100.0 % ≥2005050.0 %100.0 % ≥2503030.0 %100.0 %Intensity 1+1032100 %85.7 % 2+101100.0 %99.6 % 3+3030.0 %100 %Extent ≥10 %1029100.0 %87.28 % ≥20 %1025100.0 %89.04 % ≥30 %1020100.0 %91.23 % ≥40 %1015100.0 %93.42 % ≥50 %1014100.0 %93.86 % ≥60 %109100.0 %96.05 % ≥70 %9990.0 %96.05 % ≥80 %7470.0 %98.25 % ≥90 %4140.0 %99.56 %Table 4Comparison of FISH and IHC in ROS1 rearrangement detectionFISH ROS1 fusion positiveFISH ROS1 fusion negative*P*.Kappa ValueIHC ROS1 2-3+101\< 0.01^a^0.950IHC ROS1-, 1+0227IHC extent ≥ 60 %109\< 0.01^a^0.672IHC extent \< 60 %0219IHC H-score ≥ 150100\< 0.01^a^1.000IHC H-score \< 1500228^a^Fisher exact test

Characteristics of the positive cases {#Sec13}
-------------------------------------

Ten cases were identified as positive for ROS1 rearrangement. Most of the positive cases were female (Female: Male = 7:3) and non-smokers (7/10) with younger age (\<61 year-old, 8/10). All the cases with ROS1 rearrangement were diagnosed as adenocarcinoma (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}), and acinar pattern was the most predominant observed pattern. Eight cases could be performed histological grading, five of them got score 5 in Sica grading and 6 of them were classified as intermediate grade by WHO grading. Six of the rearrangement cases had been analyzed using direct sequencing (Table [2](#Tab2){ref-type="table"}), revealing that CD74-E6 was the most common mutation type (3/6, 50 %). The images of direct sequencing are shown in an additional figure \[see Additional file [2](#MOESM2){ref-type="media"}: Figure S1\]. Most cases showed cytoplasmic and focal granular reactivity (7/10, 70 %; Table [2](#Tab2){ref-type="table"}) \[see Additional file [3](#MOESM3){ref-type="media"}: Figure S2, c & d\]. No correlation was found between histopathology predominant patterns and IHC staining patterns (*P* = 0.645, Fisher exact test). All cases with ROS1 rearrangement were not carrying ALK, EGFR and KRAS gene aberrance.

The remaining 32 cases presented weak or focal IHC staining confirmed as ROS1 gene non-rearrangement or non-amplification by FISH. The staining patterns are shown in an additional figure \[see Additional file [3](#MOESM3){ref-type="media"}: Figure S2\]. All of them were diagnosed as adenocarcinoma. A case with an H-score of 90 and 2+ of intensity had been confirmed as ROS1 non-rearrangement by FISH. Its IHC staining was focal and represented approximately the 40 % of the tumor cells (Fig. [1f](#Fig1){ref-type="fig"}). Twenty-three of these cases underwent EGFR mutation detection, and 17 of them were confirmed as EGFR mutation (8 with exon 19 deletion and 9 with exon 21 L858R mutation). Thirty of them underwent ALK rearrangement detection, and two cases were confirmed as ALK rearrangement.

Information related to the follow-up studies {#Sec14}
--------------------------------------------

Three patients (case 3, 6 and 7) (Table [2](#Tab2){ref-type="table"}) belonging to the ten ROS1 rearrangement cases at the stage IV of their disease, received the therapy of crizotinib, a TKI approved by the Food and Drug Administration (FDA). The information related to these three patients is shown in Table [5](#Tab5){ref-type="table"}. Details of these patients can be found in a supplementary material \[see Additional file [4](#MOESM4){ref-type="media"}: Figure S3 (a-c)\].Table 5The details of follow-up studiesCase no.SurgeryHistopathologyChemotherapyROS1 detectionCT imagineTKI start timeResponseReexamination CT imagineSide effectsPatient 3Video-assisted thoracic surgery (VATS) of the left upper lobe wedge resectionInvasive mucinous adenocarcinoma with pleural invasionPemetrexed, carboplatinIHC, FISH and qRT-PCR had proved he as ROS1 rearrangement. Fusion type: CD74-E6The largest lesion in his left thoracic wall was approximate in size to 40.81 × 12.70 mm^2^Crizotinib 250 mg bid from December 2014February 2015, the lesion decreased to 26.66 × 11.69 mm^2^ in sizeOctober 2015, the largest lesion shrunk to 10.85 × 8.60 mm^2^ in sizeTiredness and constipationPatient 6Lower right lobe radical resection; Biopsy under CT guidanceInvasive adenocarcinoma with acinar predominant patternPematrexed, nadaplatin and bevacizumabIHC, FISH and qRT-PCR had proved she as ROS1 rearrangement. Fusion type: CD74-E6The largest lesion was approximated in size to 36.25 × 36.25 mm^2^ on the pleuraCrizotinib 250 mg bid from April 2014May 2014, the largest lesion decreased to 11.02 × 8.59 mm^2^ in sizeOctober 2015, the largest lesion shrunk to 10.48 × 10.33 mm^2^ in sizeEdema in lower limbs, vomiting and tirednessPatient 7Biopsy under CT guidanceInvasive adenocarcinoma with acinar pattern--IHC and FISH had proved she as ROS1 rearrangementThe largest lesion was approximate in size to 35.33 × 19.73 mm^2^Crizotinib 250 mg bid from July 2014September 2014, the lesion decreased to 26.97 × 15.12 mm^2^ in sizeNovember 2015, her largest lesion shrunk to 16.25 × 5.65 mm^2^ in sizeTiredness

Discussion {#Sec15}
==========

In the present study, three methods for ROS1 rearrangement detection have been compared. The results showed that D4D6 mAb IHC can be a reliable and feasible method for preliminary screening of ROS1 rearrangement in NSCLC, since it showed a high sensitivity and specificity. Nevertheless, the IHC cutoff value should be set at 2--3+ cytoplasmic reactivity with diffuse (≥60 % of the tumor cells) distribution or an H-score ≥150, which was similar to the conclusion of Yoshida's study \[[@CR14]\]. When we analyzed the pattern of IHC staining, we realized that the distribution of the cytoplasmic reactivity is one of the most important aspects in ROS1 IHC analysis. Indeed, a 2+ cytoplasmic reactivity intensity could be a false positive when the staining shows a focal distribution.

In order to verify and confirm the weak or focal cytoplasmic reactivity, FISH and qRT-PCR should be used as secondary confirmation. In our study, the concordant rate between qRT-PCR and FISH was 100 %, indicating that qRT-PCR could be a reliable detection method for ROS1 rearrangement. In addition, some studies have indicated that FISH cannot clearly reveal the rearrangements on the same chromosome, such as GOPC (FIG)-ROS1 and EZR-ROS1 \[[@CR4], [@CR13]\]. Therefore, qRT-PCR can be used as a second confirmatory test for revealing these rearrangements. In contrast, the cases that resulted negative after qRT-PCR analysis should be confirmed by FISH since the primers of qRT-PCR do not contain unknown fusion partners \[[@CR12]\]. Finally, we designed a protocol for the detection of ROS1 rearrangement shown in Fig. [2](#Fig2){ref-type="fig"} that encompassed these considerations.Fig. 2The routine protocol for ROS1 arrangements detection in NSCLC. IHC with D4D6 mAb can be preliminary screening tool for ROS1 rearrangement detection in NSCLC, and the IHC cutoff value should be set at 2--3+ cytoplasmic reactivity with diffuse (≥60 % of the tumor cells) distribution or an H-score ≥150; FISH and qRT-PCR should be used as the secondary confirmation in the cases with weak of focal IHC staining

The clinical characteristics and pathological pattern of patients with ROS1 rearrangements were also discussed in this study. Even though there were no significant difference between ROS1 rearrangement and non-rearrangement patients, the cases with ROS1 rearrangement were mostly females at a younger ages and non-smokers with adenocarcinoma, which was similar to the results of some previous studies \[[@CR20]--[@CR22]\]. Most cases were classified as intermediate grade by WHO grading, however, five of them obtained score 5 in Sica grading, which indicated these cases containing high grade patterns as well. This result revealed that ROS1 rearrangement might become a prognosis biomarker of NSCLC. However, this finding should be confirmed in future study. Most ROS1 rearrangement cases presented cytoplasmic and focal granular staining pattern in the IHC staining, which was similar to the finding of some previous studies \[[@CR14], [@CR23]\]. However, the correlation between histopathology patterns and IHC staining patterns, as well as the correlation between fusion types and IHC reactivity patterns were not found due to the lack of ROS1 rearrangement cases. In addition, all the ROS1 rearrangement cases in our study were not carrying ALK rearrangement, as well as EGFR and KRAS mutations. Even though the overlapping phenomenon has been reported in some rare cases \[[@CR8], [@CR22]\], the result in our study indicated that general oncogene mutations not necessarily overlap in the same patient \[[@CR4], [@CR21]\].

Thirty-two cases with IHC weak or focal reactivity had been confirmed as ROS1 non-rearrangement. Although we had set the tissue with IHC strong reactivity as the positive control to avoid misunderstanding with the background staining, and chosen two areas with IHC reactivity in each FFPE block to decrease heterogeneity in establishing TMAs, these weak or focal staining might still be related to background staining or tissue heterogeneity. Nevertheless, among these cases, 17 were carrying EGFR mutation and 2 were harboring ALK rearrangement. To explain this phenomenon, Li et al. \[[@CR24]\] investigated the expression of ROS1 mRNA in NSCLC, and found that the level of ROS1 mRNA increased either in ALK rearrangements or EGFR mutation specimens. However, the specific mechanism was unknown. We speculated that the weak or focal staining of ROS1 IHC may result from cross-talk mechanism of EGFR, ALK and ROS1 pathways, which is similar to the mechanism of EGFR mutation in NSCLC with MET proto-oncogene protein expression \[[@CR25], [@CR26]\]. However, EGFR mutation and ALK rearrangement detection was not possible on the remaining 9 and 2 cases, respectively. Thus, we cannot conclude that there was a correlation between weak or focal staining of ROS1 IHC and other genes aberrance.

After all the analyses, three patients with stage IV and ROS1 rearrangement underwent crizotinib therapy. All of them showed a partial response (PR) after 2 to 8 weeks, which was similar to some previous studies \[[@CR8], [@CR24]\]. In addition, even two patients had received chemotherapy before TKI therapy (patient 3 & 6), both of them had the same response to crizotinib as the other patient (patient 7), which indicated that crizotinib is also sensitive to the patients after chemotherapy. These three patients underwent crizotinib therapy for at least 11 months, reaching an average PR after 13.7 months. Since our patients were under a follow-up schedule, we could not estimate the progression-free survival (PFS). A large-scale study showed that the PFS of patients under crizotinib carrying ROS1 rearrangement was longer than the patients carrying ALK rearrangement undergoing the same therapy, suggesting the possible mechanism that imply crizotinib binding more tightly to ROS1 than to ALK \[[@CR8]\].

Tiredness was the most common symptom during the therapy, and a patient (patient 6) also suffered from both lower limbs edema without cardiac dysfunction, which is one of the most common side effects observed in a previous study \[[@CR8]\]. However, the correlation between TKI response and fusion partners had not been discussed because of the reduced ROS1 rearrangement cases to draw relevant conclusions. Because the FDA has recently approved crizotinib as a TKI to ROS1 rearrangement of NSCLC, we consider that the patients potentially harboring ROS1 rearrangement can be recruited by preliminary screening, therefore, more patients can receive TKI therapy, and the correlation between fusion types and TKI response or histopathology can be analyzed.

There are some limitations in our study. First of all, the qRT-PCR analysis was performed in only 159 cases. In order to analyze the concordance between qRT-PCR and FISH, all the recruited cases should be tested by qRT-PCR. However, some of the biopsied cases had insufficient amount of tissue to perform the qRT-PCR. Moreover, in order to clarify the relationship between fusion partners and TKIs response, and the correlation between fusion types and histopathology, more positive cases are needed. Finally, the relation between faint and weak staining of ROS1 IHC and other gene aberrance was not clear since not all faint and weak staining cases underwent EGFR mutation and ALK rearrangement detection. Future studies will include more patients carrying ROS1 arrangements (i.e. young, female, non-smokers with adenocarcinoma) to obtain more positive cases for the analysis.

Conclusions {#Sec16}
===========

In conclusion, IHC can be a reliable and effective method for ROS1 rearrangements preliminary screening in patients with NSCLC thanks to the high sensitivity and specificity of IHC using the D4D6 mAb, while cutoff should be set at diffusely (≥60 % tumor cells) 2--3+ cytoplasmic reactivity and an H-score ≥150. FISH and qRT-PCR can be used as confirmation analysis. Young, female, and non-smoking patients with adenocarcinoma and without other RTKs aberrance should undergo tests for ROS1 rearrangement because patients with these characteristics may carry ROS1 rearrangement. TKI therapy with crizotinib is effective in patients with ROS1 rearrangements at advanced stages.
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